ICE HOCKEY DATABASE SCHEMA DESIGN: FOR NATIONAL TEAM\u27S BIOMECHANICAL ANALYSIS

This study presented database schema to manage ice hockey data shown in official record of World Championships. We selected data fields to design database schema considering which fields were contributing to the victory. We also sorted all fields into six tables to reflect the elements of ice hockey games; Game Information, Team Information, Offensice Stats, Defence Stats, Face-off Stats, Time On Ice Stats. This study was a prior research designing database schema in which the analysis of ice hockey official record is used to advance from statistical models to data science techniques. After storing raw data pre-processed into the database, researcher can analyze biomechanically to improve performance

Nutritional compositions in roots, twigs, leaves, fruit pulp, and seeds from pawpaw (Asimina triloba [L.] Dunal) grown in Korea

Pawpaw (Asimina triloba L.) roots, twigs, leaves, fruit, and seeds were analyzed for their nutritional compositions. Seeds exhibited significantly higher levels of crude protein, lipid, fiber, and dietary fiber than those of the other parts. Sucrose in fruit was 9321.24 mg%, which was the highest among the samples. The total essential amino acid to total amino acid ratio was highest in the leaves, and the leaves contained the highest amount of potassium. The calcium content ranged between 8.15-153.41 mg%. Oleic and linoleic acids in seeds were 5905.11 and 8045.56 mg%, respectively, which were the highest among the pawpaw parts. The highest amount of linolenic acid was measured in the leaves, and β-carotene, vitamin C, and vitamin E were also the most abundant in the leaves. These results suggest that every part of pawpaw is a good source of an important food item. Additionally, this study provides basic data for improving the sitological value of pawpaw

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

AbstractBACKGROUND: We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GEMOX) resulted in greater antitumor activity and might be a treatment option for patients with biliary tract cancers (BTCs). Molecular subgroup analysis of treatment outcomes in patients who had specimens available for analysis was undertaken. METHODS: Epidermal growth factor receptor (EGFR), KRAS, and PIK3CA mutations were evaluated using peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp reactions. Survival and response rates (RRs) were analyzed according to the mutational status. Sixty-four patients (48.1%) were available for mutational analysis in the chemotherapy alone group and 61 (45.1%) in the chemotherapy plus erlotinib group. RESULTS: 1.6% (2/116) harbored an EGFR mutation (2 patients; exon 20), 9.6% (12/121) harbored a KRAS mutation (12 patients; exon 2), and 9.6% (12/118) harbored a PIK3CA mutation (10 patients, exon 9 and 2 patients, exon 20). The addition of erlotinib to GEMOX in patients with KRAS wild-type disease (n = 109) resulted in significant improvements in overall response compared with GEMOX alone (30.2% vs 12.5%, P = .024). In 95 patients with both wild-type KRAS and PIK3CA, there was evidence of a benefit associated with the addition of erlotinib to GEMOX with respect to RR as compared with GEMOX alone (P = .04). CONCLUSION: This study demonstrates that KRAS mutational status might be considered a predictive biomarker for the response to erlotinib in BTCs. Additionally, the mutation status of PIK3CA may be a determinant for adding erlotinib to chemotherapy in KRAS wild-type BTCs

PPM1A Controls Diabetic Gene Programming through Directly Dephosphorylating PPAR?? at Ser273

Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a master regulator of adipose tissue biology. In obesity, phosphorylation of PPAR gamma at Ser273 (pSer273) by cyclin-dependent kinase 5 (CDK5)/extracellular signal-regulated kinase (ERK) orchestrates diabetic gene reprogramming via dysregulation of specific gene expression. Although many recent studies have focused on the development of non-classical agonist drugs that inhibit the phosphorylation of PPAR gamma at Ser273, the molecular mechanism of PPAR gamma dephosphorylation at Ser273 is not well characterized. Here, we report that protein phosphatase Mg2+/Mn2+-dependent 1A (PPM1A) is a novel PPAR gamma phosphatase that directly dephosphorylates Ser273 and restores diabetic gene expression which is dysregulated by pSer273. The expression of PPM1A significantly decreases in two models of insulin resistance: diet-induced obese (DIO) mice and db/db mice, in which it negatively correlates with pSer273. Transcriptomic analysis using microarray and genotype-tissue expression (GTEx) data in humans shows positive correlations between PPM1A and most of the genes that are dysregulated by pSer273. These findings suggest that PPM1A dephosphorylates PPAR gamma at Ser273 and represents a potential target for the treatment of obesity-linked metabolic disorders